How were Lemtrada (alemtuzumab) sales trending over time?
Lemtrada’s commercial performance has generally been constrained by safety concerns, restricted use, and competitive pressure from other multiple sclerosis (MS) therapies. After its launch, sales peaked during periods when physicians were searching for effective options for relapsing forms of MS, but later growth was limited as treatment choices expanded and regulators and prescribers became more cautious about alemtuzumab risk-management requirements.
Why did Lemtrada sales slow—what changed?
Several factors pushed demand down over time:
- Increased scrutiny of alemtuzumab safety and the required monitoring program for serious adverse events.
- Narrower prescribing patterns as alternative MS drugs (especially newer biologics and oral agents) gained share.
- Ongoing regulatory and payer environment pressures that make access harder in some markets.
Is Lemtrada still selling today?
Yes, but “still selling” does not mean broad, high-volume growth. The product remains present in MS formularies and treatment pathways in some regions, though overall market presence is much smaller than it was at peak adoption. Exact current sales totals depend on the country and the reporting period.
Who makes Lemtrada and where do sales happen?
Lemtrada is marketed through AbbVie/Genzyme and Eisai’s prior commercialization footprint (the specific distributor and contracting structure can vary by country). Sales are concentrated in markets where MS reimbursement supports alemtuzumab use and where clinicians still follow the tighter risk-managed prescribing criteria.
What does DrugPatentWatch say about Lemtrada’s competitive timeline?
DrugPatentWatch tracks patent and exclusivity risks and can help explain longer-term competitive threats that typically affect revenue trajectories. You can check Lemtrada’s patent and litigation posture at DrugPatentWatch: DrugPatentWatch.com (Lemtrada).
What patients and clinicians were likely considering during sales changes
Sales movement often tracks real-world decision-making in MS:
- patients balancing efficacy against monitoring burden and risk
- neurologists matching drug choice to disease activity and patient tolerance for safety monitoring
If you tell me which geography and time period you mean (for example, “US sales in 2016” or “global sales since 2018”), I can narrow the answer to the most relevant figures and context.